Synthesis of N-(3-arylprop-2-ynyl)substituted olanzapine derivatives as potential inhibitors of PDE4B

[1]  M. Pal,et al.  Pd-mediated construction of a cyclopentane ring fused with indoles. , 2013, Chemical communications.

[2]  Rajnikanth Sunke,et al.  Vinylic amino group activation: a new and general strategy leading to functionalized fused heteroaromatics. , 2013, Chemical communications.

[3]  K. Mukkanti,et al.  Novel N-indolylmethyl substituted olanzapine derivatives: their design, synthesis and evaluation as PDE4B inhibitors. , 2013, Organic & biomolecular chemistry.

[4]  K. Mukkanti,et al.  Construction of a six-membered fused N-heterocyclic ring via a new 3-component reaction: synthesis of (pyrazolo)pyrimidines/pyridines. , 2012, Chemical communications.

[5]  K. Parsa,et al.  Pd-mediated new synthesis of pyrroles: their evaluation as potential inhibitors of phosphodiesterase 4. , 2011, Chemical communications.

[6]  K. Parsa,et al.  A new three-component reaction: green synthesis of novel isoindolo[2,1-a]quinazoline derivatives as potent inhibitors of TNF-α. , 2011, Chemical communications.

[7]  M. Pal.  Palladium-Catalyzed Alkynylationof Aryl and Hetaryl Halides: A Journey from Conventional PalladiumComplexes or Salts to Palladium/Carbon , 2009 .

[8]  M. Pal,et al.  Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. , 2008, Journal of medicinal chemistry.

[9]  S. Siegel,et al.  Antipsychotic-Like Properties of Phosphodiesterase 4 Inhibitors: Evaluation of 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724) with Auditory Event-Related Potentials and Prepulse Inhibition of Startle , 2008, Journal of Pharmacology and Experimental Therapeutics.

[10]  A. Apkarian,et al.  Shared mechanisms between chronic pain and neurodegenerative disease , 2006 .

[11]  Kam Y. J. Zhang,et al.  Structural basis for the activity of drugs that inhibit phosphodiesterases. , 2004, Structure.

[12]  D. Allison,et al.  Antipsychotic-induced weight gain: a review of the literature. , 2001, The Journal of clinical psychiatry.

[13]  F. Bymaster,et al.  Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and α 1-adrenergic receptors in vitro , 1999, Schizophrenia Research.

[14]  T. Keller,et al.  Enantiodivergent Synthesis of (R)- and (S)-Rolipram , 1998 .

[15]  M. Billah,et al.  Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D. , 1997, Biochemical and biophysical research communications.

[16]  C R Ashby,et al.  Pharmacological actions of the atypical antipsychotic drug clozapine: A review , 1996, Synapse.

[17]  J. Siuciak.  The Role of Phosphodiesterases in Schizophrenia , 2008, CNS drugs.

[18]  N C Andreasen,et al.  Positive and negative symptoms: historical and conceptual aspects. , 1990, Modern problems of pharmacopsychiatry.